Roche Holding entered into a collaboration and licensing agreement with Hansoh Pharmaceutical Group, continuing a dealmaking spree in China with a partnership that could net the Chinese drugmaker more than $15 billion.
Hansoh will receive $400 million upfront from Roche and $110 million after a year, and be eligible for potential payments subject to targets totaling more than $15 billion, it said Monday. Hansoh would also get royalties on potential sales if the products are commercialized, it added.